Screening-detected atrial fibrillation is associated with a high risk of heart failure, comparable to known atrial fibrillation, and is not a benign condition.
Abstract
Abstract Aims Atrial fibrillation is associated with increased risks of stroke, heart failure, and death. While stroke prevention is a key focus, heart failure is more frequent and a major contributor to mortality in atrial fibrillation. This study aimed to assess the incidence and timing of heart failure in screening-detected atrial fibrillation. Methods and results This post hoc analysis included participants without prior heart failure from the STROKESTOP and STROKESTOP II randomized screening studies, in which individuals aged 75–76 years were invited to ECG-based atrial fibrillation screening. Incident heart failure diagnoses were obtained from national registries. Incidence rates were calculated per 100 person-years, and Cox regression was used to estimate hazard ratios (HRs). In STROKESTOP, 23% of participants with screening-detected atrial fibrillation developed heart failure (3.76 per 100 person-years), compared with 4.43 in patients with known atrial fibrillation and 1.08 in patients without atrial fibrillation. Screening-detected atrial fibrillation was associated with a three-fold higher heart failure risk vs. no atrial fibrillation (adjusted HR 3.19) and a risk comparable to known atrial fibrillation (adjusted HR 2.86). In STROKESTOP II, 20% developed heart failure (4.19 per 100 person-years), compared with 3.52 in known atrial fibrillation and 0.93 without atrial fibrillation. Screening-detected atrial fibrillation was associated with a four-fold higher heart failure risk vs. no atrial fibrillation (adjusted HR 4.73) and a higher risk than known atrial fibrillation (adjusted HR 2.59). Conclusion Screening-detected atrial fibrillation is associated with a high risk of heart failure, comparable to known atrial fibrillation, and is not a benign condition.
BACKGROUND AND AIMS
Early rhythm-control improves cardiovascular outcomes in patients with atrial fibrillation (AF). Its effectiveness in patients with cancer is unclear. This study evaluated the effects of cancer history on early rhythm-control in the EAST-AFNET 4 trial.
METHODS
This secondary analysis of EAST-AFNET...
D. Ismaili, A. Suling, K. Borof et al.· Europace· 0 citations
Background: Atrial fibrillation is the most common cardiac arrhythmia and increases the risk of stroke, heart failure, and mortality. NVAF accounts for most AF cases, with treatment focused on anticoagulation and rate or rhythm control. DOAC use has increased globally, but evidence from Bangladesh remains limited. This...
M. Sufian, A. N. M. Monowarul Kadir, Maryam Zahid et al.· Scholars Journal of Applied...· 0 citations
Prediabetes was associated with a modestly increased risk of new-onset AF, particularly persistent AF, and was associated with HF development among individuals without established arrhythmia.
K. Ukita, Lotta Nowak, F. Schmelter et al.· Clinical Research in Cardiol...· 0 citations
Introduction and Objectives: Patients with atrial fibrillation (AF) and prior ischemic stroke or transient ischemic attack (TIA) are at high risk of recurrent thromboembolic events. Although direct oral anticoagulants (DOACs) have progressively replaced vitamin K antagonists (VKAs), it remains uncertain whether prior s...
Janusz Bednarski, Michał Wojewódzki, M. Szewczak et al.· Journal of Clinical Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.